Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

K. Vochoskova, SR. McWhinney, M. Fialova, M. Kolenic, F. Spaniel, P. Furstova, P. Boron, Y. Okaji, P. Trancik, T. Hajek

. 2024 ; 67 (1) : e59. [pub] 20240926

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018857

Grantová podpora
NV16-32791A Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. METHODS: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors. RESULTS: Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications. CONCLUSIONS: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018857
003      
CZ-PrNML
005      
20241024111126.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1192/j.eurpsy.2024.1761 $2 doi
035    __
$a (PubMed)39323217
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vochoskova, Kristyna $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0009000170613043
245    10
$a Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis / $c K. Vochoskova, SR. McWhinney, M. Fialova, M. Kolenic, F. Spaniel, P. Furstova, P. Boron, Y. Okaji, P. Trancik, T. Hajek
520    9_
$a BACKGROUND: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. METHODS: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors. RESULTS: Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications. CONCLUSIONS: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.
650    _2
$a lidé $7 D006801
650    12
$a antipsychotika $x terapeutické užití $x škodlivé účinky $7 D014150
650    12
$a hmotnostní přírůstek $x účinky léků $7 D015430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a psychotické poruchy $x farmakoterapie $7 D011618
650    _2
$a dospělí $7 D000328
650    12
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    12
$a index tělesné hmotnosti $7 D015992
650    12
$a schizofrenie $x farmakoterapie $7 D012559
650    _2
$a mladý dospělý $7 D055815
650    _2
$a risperidon $x terapeutické užití $x škodlivé účinky $7 D018967
650    _2
$a olanzapin $x terapeutické užití $7 D000077152
650    _2
$a polypharmacy $7 D019338
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a McWhinney, Sean R $u Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
700    1_
$a Fialova, Marketa $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000337972965
700    1_
$a Kolenic, Marian $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000223823478 $7 xx0234929
700    1_
$a Spaniel, Filip $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/000000033479696X $7 xx0102926
700    1_
$a Furstova, Petra $u National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000323771388
700    1_
$a Boron, Petra $u Psychiatric Hospital Bohnice, Prague, Czech Republic
700    1_
$a Okaji, Yurai $u Psychiatric Hospital Bohnice, Prague, Czech Republic
700    1_
$a Trancik, Pavel $u Psychiatric Hospital Bohnice, Prague, Czech Republic
700    1_
$a Hajek, Tomas $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychiatry, Dalhousie University, Halifax, NS, Canada $1 https://orcid.org/0000000302818458 $7 mzk2002112973
773    0_
$w MED00001658 $t European psychiatry : the journal of the Association of European Psychiatrists $x 1778-3585 $g Roč. 67, č. 1 (2024), s. e59
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39323217 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111120 $b ABA008
999    __
$a ok $b bmc $g 2201615 $s 1230830
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 67 $c 1 $d e59 $e 20240926 $i 1778-3585 $m European psychiatry : the journal of the Association of European Psychiatrists $n Eur Psychiatry $x MED00001658
GRA    __
$a NV16-32791A $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace